FDA Alerts
The FDA recently approved a new topical retinoid for the treatment of acne on both the face and the trunk.
The FDA approved the expanded indication of topical dapsone 7.5% gel for the treatment of acne vulgaris in patients aged 9 to 11 years.
The FDA approved a new treatment option for patients with oral ulcers associated with Behçet disease.
The FDA has approved the first treatment option for chronic, inadequately controlled rhinosinusitis with nasal polyps.
The FDA approved a new foam treatment for adolescents with plaque psoriasis on the scalp and body.
The FDA has approved a second biosimilar to etanercept for the treatment of various autoimmune conditions.
The FDA has approved a new topical therapy for the treatment of plaque psoriasis in adult patients.
The FDA approved a new biologic for the treatment of moderate to severe plaque psoriasis.
The FDA approved dupiliumab for the treatment of moderate to severe atopic dermatitis in adolescents.
The FDA has approved a new biosimilar for patients with various autoimmune diseases, including psoriasis and psoriatic arthritis.